Monitoring bortezomib therapy in multiple myeloma: Screening of cyclin D1 overexpression as a potential prognostic marker for response to treatment

8614 Background: Cyclin D1 (CCND1), 2 (CCND2) and 3 (CCND3) are overexpressed in almost all MM and their deregulation has prognostic value. As cyclins are substrates of the proteasome, proteasome i...